It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Coronavirus disease 2019 (COVID-19) pandemic is affecting millions of patients worldwide. The consequences of initial exposure to SARS-CoV-2 go beyond pulmonary damage, with a particular impact on lipid metabolism. Decreased levels in HDL-C were reported in COVID-19 patients. Since HDL particles display antioxidant, anti-inflammatory and potential anti-infectious properties, we aimed at characterizing HDL proteome and functionality during COVID-19 relative to healthy subjects. HDLs were isolated from plasma of 8 severe COVID-19 patients sampled at admission to intensive care unit (Day 1, D1) at D3 and D7, and from 16 sex- and age-matched healthy subjects. Proteomic analysis was performed by LC-MS/MS. The relative amounts of proteins identified in HDLs were compared between COVID-19 and controls. apolipoprotein A-I and paraoxonase 1 were confirmed by Western-blot analysis to be less abundant in COVID-19 versus controls, whereas serum amyloid A and alpha-1 antitrypsin were higher. HDLs from patients were less protective in endothelial cells stiumalted by TNFα (permeability, VE-cadherin disorganization and apoptosis). In these conditions, HDL inhibition of apoptosis was blunted in COVID-19 relative to controls. In conclusion, we show major changes in HDL proteome and decreased functionality in severe COVID-19 patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Université de La Réunion, INSERM, UMR 1188 Diabète atherothombose Réunion Océan Indien (DéTROI), Saint-Denis de La Réunion, France (GRID:grid.7429.8) (ISNI:0000000121866389)
2 Université de La Réunion, INSERM, UMR 1188 Diabète atherothombose Réunion Océan Indien (DéTROI), Saint-Denis de La Réunion, France (GRID:grid.7429.8) (ISNI:0000000121866389); CHU Bichat-Claude Bernard, AP-HP, Service d’Anesthésie-Réanimation, Paris, France (GRID:grid.411119.d) (ISNI:0000 0000 8588 831X)
3 CHU Bichat-Claude Bernard, AP-HP, Service d’Anesthésie-Réanimation, Paris, France (GRID:grid.411119.d) (ISNI:0000 0000 8588 831X); Université de Paris, UFR Denis Diderot, Paris, France (GRID:grid.411119.d)
4 CHU Bichat-Claude Bernard, AP-HP, Service de Biochimie, Paris, France (GRID:grid.411119.d) (ISNI:0000 0000 8588 831X)
5 Clinique Sainte-Clotilde, Groupe Clinifutur, Sainte-Clotilde, La Réunion, France (GRID:grid.411119.d)
6 Université de La Réunion, UMR Processus Infectieux en Milieu Insulaire Tropical (PIMIT), INSERM 1187, CNRS 9192, IRD 249, Sainte-Clotilde, La Réunion, France (GRID:grid.411119.d)
7 CHU de La Réunion, Service des maladies infectieuses, Saint-Denis, France (GRID:grid.440886.6) (ISNI:0000 0004 0594 5118)
8 CHU Bichat-Claude Bernard, AP-HP, Service d’Anesthésie-Réanimation, Paris, France (GRID:grid.411119.d) (ISNI:0000 0000 8588 831X); Université de Paris, UFR Denis Diderot, Paris, France (GRID:grid.411119.d); Université Diderot, Inserm UMR 1152 Physiopathologie Et Épidémiologie Des Maladies Respiratoires, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
9 Université de La Réunion, INSERM, UMR 1188 Diabète atherothombose Réunion Océan Indien (DéTROI), Saint-Denis de La Réunion, France (GRID:grid.7429.8) (ISNI:0000000121866389); CHU de La Réunion, Service de neuro-réanimation, Saint-Pierre, France (GRID:grid.440886.6) (ISNI:0000 0004 0594 5118)
10 Université de La Réunion, INSERM, UMR 1188 Diabète atherothombose Réunion Océan Indien (DéTROI), Saint-Denis de La Réunion, France (GRID:grid.7429.8) (ISNI:0000000121866389); CHU de La Réunion, CIC-EC 1410, Saint-Pierre, France (GRID:grid.440886.6) (ISNI:0000 0004 0594 5118)